Choose Medical News By Speciality
Some feed pages can be slow to load
Some feed pages can be slow to load
In women who have BRCA1/2 mutations and primary breast cancer, radiation therapy might increase the risk for cancer in the other breast.
Progression-free survival was longer with selpercatinib than with platinum-based chemotherapy plus pemetrexed with or without pembrolizumab.
Adding an immune checkpoint inhibitor to first-line chemotherapy improves overall survival, but only in patients with combined positive scores of ≥1% for PD-L1.
This combination resulted in higher PFS and response rates than trifluridine-tipiracil or regorafenib.
The addition of pembrolizumab to platinum-based chemotherapy improved overall survival compared with chemotherapy alone in patients with advanced pleural mesothelioma.
Single Use Tubing Sets Brochure